DepoCyt data

CHIR and DEPO released results from a controlled, non-blinded Phase III trial in 61 patients, of whom 54 were evaluable. Patients received either the sustained-release cytarabine or the standard chemotherapy, methotrexate.

Response was defined as the absence of malignant cells in two consecutive samples of cerebrospinal fluid, and lack of disease progression as assessed by a neurological exam. Partial responses were not evaluated. ...